Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials
Authors:
- Johannes GrandJGJohannes Grand
- Kristina MigerKMKristina Miger
- Ahmad SajadiehASAhmad Sajadieh
- Lars KøberLKLars Køber
- Christian Torp-PedersenCTChristian Torp-Pedersen
- Georg ErtlGEGeorg Ertl
- José López-SendónJLJosé López-Sendón
- Aldo Pietro MaggioniAldo Pietro Maggioni
- John R. TeerlinkJTJohn R. Teerlink
- Naoki SatoNSNaoki Sato
- Marco MetraMMMarco Metra
- 1 April 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (4) , 368-378
Abstract
Background: Hypotensive events and drops in systolic blood pressure (SBP-drop) are frequent in patients hospitalized with acute heart failure. We investigated whether SBP-drops are associated with outcomes in patients treated with serelaxin. Methods: Patient-level retrospective analyses of 4 prospective trials investigating serelaxin in acute heart failure. Main inclusion criteria were SBP 125 to 180 mm Hg, pulmonary congestion, and elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide). SBP-drops were prospectively defined as SBP100 mm Hg, a drop from baseline of 40 mm Hg from baseline. Outcomes were a short-term composite outcome (worsening heart failure, hospital readmission for heart failure or all-cause mortality through 14 days) and 180-day mortality. Results: Overall, 2559/11 226 (23%) patients had an SBP-drop. SBP-drop, versus no SBP-drop, was associated with a worse outcome: cumulative incidence of 180-day mortality (11% versus 9%, hazard ratio [HR]. 1.21 [95% CI, 1.05–1.39]; P =0.009) and the short-term outcome (11% versus 9%, HR, 1.29 [95% CI, 1.13–1.49]; P P =0.0005) and 1.22 (95% CI, 0.97–1.56; P =0.09), for each component respectively, with a P value for interaction of 0.05. SBP-drops were associated with a worse short-term outcome in the placebo group (HR, 1.46 [95% CI, 1.19–1.79]; P =0.0003), but not in the serelaxin-group (HR, 1.18 [95% CI, 0.97–1.42]; P =0.10); P interaction=0.003. Conclusions: SBP-drops in patients with acute heart failure and normal to high SBP at admission is associated with worse short- and long-term outcomes especially for SBP <100 mm Hg. However, in patients treated with the intravenous vasodilator serelaxin, SBP-drops seemed less harmful. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02064868, NCT02007720, NCT01870778, NCT00520806.Keywords
This publication has 26 references indexed in Scilit:
- The Burden of Acute Heart Failure on U.S. Emergency DepartmentsJACC: Heart Failure, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart FailureCirculation, 2013
- Long-term survival following acute heart failure: The Acute Heart Failure Database Main registry (AHEAD Main)European Journal of Internal Medicine, 2013
- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialThe Lancet, 2013
- Effect of Nesiritide in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011
- Dyspnoea and Worsening Heart Failure in Patients with Acute Heart Failure: Results from the Pre-RELAX-AHF StudyEuropean Journal of Heart Failure, 2010
- Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart FailureJAMA, 2006
- Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspneaBiomedicine & Pharmacotherapy, 2005
- The Pathogenesis of Acute Pulmonary Edema Associated with HypertensionNew England Journal of Medicine, 2001
- Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedemaThe Lancet, 1998